SWOG clinical trial number
CTSU/E1908

A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab

Closed
Phase
Published
Abbreviated Title
Phase II Alemttuzumab + Standard vs. Low Dose Rituximab for Elderly CLL
Activated
11/15/2010
Closed
10/31/2013
Participants
CTSU

Research committees

Leukemia

Treatment

Rituximab Campath-1H

Publication Information Expand/Collapse

2016

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)

C Zent;X Zang;RP Ketterling;C Hanson;E Libby;J Barrientos;T Call;J Call;JE Chang;JJ Liu;A Calvo;H Lazarus;J Rowe;S Luger;M Litzow;M Tallman American Journal of Hematology Mar;91(3):308-312

PMid: PMID26662208 | PMC number: PMC4806550

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A042001

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
Accrual
49%
Open
Phase
SWOG Clinical Trial Number
CTSU/AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Research Committee(s)
Leukemia
Activated
12/04/2020
Open